• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Hutchmed China Ltd ADR (NQ: HCM )

    19.95 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 30
    Open 19.95
    Bid (Size) 21.14 (6)
    Ask (Size) 21.35 (1)
    Prev. Close 19.95
    Today's Range 19.95 - 19.95
    52wk Range 11.93 - 21.92
    Shares Outstanding 871,256,270
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
    Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
    From HUTCHMED (China) Limited
    Via GlobeNewswire

    Performance

    YTD
    +13.93%
    +13.93%
    1 Month
    +14.39%
    +14.39%
    3 Month
    +8.07%
    +8.07%
    6 Month
    +18.26%
    +18.26%
    1 Year
    +22.47%
    +22.47%

    More News

    Read More
    International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
    From Virtual Investor Conferences
    Via GlobeNewswire
    HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    Hutchmed scores U.S. success with cancer drug, but profits still dip
    Via Benzinga
    HUTCHMED Reports 2024 Interim Results and Provides Business Updates
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    Why HUTCHMED Stock Is Moving Higher Friday
    Via Benzinga
    HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED to Announce 2024 Half-Year Financial Results
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.